医学
观察研究
ABO血型系统
肝硬化
内科学
胃肠病学
A组
疾病
队列研究
B组
随机对照试验
肝病
酒精性肝病
原发性胆汁性肝硬化
队列
流行病学
作者
Isabelle Ollivier‐Hourmand,Yohann Repesse,Pierre Nahon,Cendrine Chaffaut,Thông Dao,Thi Thu Nga Nguyen,Patrick Marcellin,Dominique Roulot,Victor De Ledinghen,Stanislas Pol,Dominique Guyader,Isabelle Archambeaud,Fabien Zoulim,Frédéric Oberti,Albert Tran,Jean‐Pierre Bronowicki,Louis D'Alteroche,Denis Ouzan,Jean‐Marie Peron,Jean‐Pierre Zarski
摘要
BACKGROUND AND AIMS: Non-O blood group promotes deep vein thrombosis and liver fibrosis in both general population and hepatitis C. We aimed to evaluate the influence of Non-O group on the outcome of Child-Pugh A cirrhotic patients. METHODS: We used two prospective cohorts of Child-Pugh A cirrhosis due to either alcohol or viral hepatitis. Primary end point was the cumulated incidence of 'Decompensation' at 3 years, defined as the occurrence of ascites , hydrothorax, encephalopathy, gastrointestinal bleeding related to portal hypertension, or bilirubin >45 μmol/L. Secondary end points were the cumulated incidences of (1) 'Disease Progression' including a « decompensation» or « the occurrence of one or more parameters » among: prothrombin time (PT) <45%, albumin <28 g/L, Child-Pugh worsening (B or C vs A or B, C vs B), hepatorenal syndrome, and hepato-pulmonary syndrome, (2) other events such as non-malignant portal vein thrombosis (nmPVT), and (3) overall survival. RESULTS: Patients (n = 1789; 59.9% Non-O group; 40.1% group O) were followed during a median of 65.4 months. At 3 years cumulated incidence of Decompensation was 8.3% in Non-O group and 7.2% in group O (P = .27). Cumulated incidence of Disease Progression was 20.7% in Non-O group and 18.9% in group O (P = .26). Cumulated incidence of nmPVT was 2.7% in Non-O group and 2.8% in group O (P = .05). At 3 years overall survival was 92.4% in Non-O group and 93.4% in group O (P = 1). CONCLUSION: Non-O group does not influence disease outcome in Child-Pugh A cirrhotic patients. Clinicals trial number NCT03342170.
科研通智能强力驱动
Strongly Powered by AbleSci AI